Investigational drug · Phase 2
QLS1410
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Primary Aldosteronism.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "QLS1410"
First trial start
2026
Jun 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "QLS1410", any sponsor or status.
Conditions studied
As listed on its trial records.
- Primary Aldosteronism
Largest trials
Live from ClinicalTrials.gov: studies naming "QLS1410" as an intervention, largest first.
- QLS1410 in Participants With Uncontrolled HypertensionPivotal-lookingEnrolling by invitation
Qilu Pharmaceutical Co., Ltd.Industry
NCT07489612 · 260 participants (planned) · Start Apr 2026 · Primary completion Dec 2026
Drug: Dose 1 of QLS1410; Dose 2 of QLS1410 and 2 more · For: Hypertension (HTN)
Sites: Jinan, China
- A Phase II Clinical Trial to Evaluate the Efficacy and Safety of QLS1410 Tablets in Patients With Uncontrolled Hypertension Who Are Receiving One or More Background Drug TreatmentsPivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07927556 · 260 participants (planned) · Start Nov 2026 · Primary completion Dec 2027
Drug: Dose 1 of QLS1410; Dose 2 of QLS1410 and 2 more · For: Uncontrolled Hypertension
- A Phase I Trial of QLS1410 in Healthy Chinese Adults and Participants With Mild Essential HypertensionNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07152444 · 78 participants (planned) · Start Sep 2025 · Primary completion May 2026
Drug: QLS1410 (CYP11B2 inhibitor); placebo · For: Uncontrolled Hypertension
Sites: Beijing, China
- Study of QLS1410 in the Treatment of Primary Aldosteronism.Not yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07550465 · 60 participants (planned) · Start Jun 2026 · Primary completion Apr 2027
Drug: QLS1410; Placebo · For: Primary Aldosteronism
- A Food Effect Study of QLS1410 in Healthy Chinese AdultsNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07358858 · 12 participants (planned) · Start Jan 23, 2026 · Primary completion Feb 7, 2026
Drug: QLS1410 · For: Uncontrolled Hypertension
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Primary Aldosteronism
- HRS-1780Phase 33 trials
Shandong Suncadia Medicine Co., Ltd. · Chronic Kidney Disease, Uncontrolled or Resistant Hypertension, Primary Aldosteronism
- SAL0140Phase 23 trials
Shenzhen Salubris Pharmaceuticals Co., Ltd. · Primary Aldosteronism, Chronic Kidney Disease, Uncontrolled Hypertension
- SYH2072Phase 22 trials
InnovStone Therapeutics Limited · Uncontrolled Hypertension, Resistant Hypertension, Primary Aldosteronism
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.